首页> 外文期刊>The Journal of Nuclear Medicine >Development of a novel 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent.
【24h】

Development of a novel 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent.

机译:具有高亲和力的新型99mTc-螯合物-双膦酸酯的开发作为骨闪烁显像剂。

获取原文
获取原文并翻译 | 示例
           

摘要

In bone scintigraphy using (99m)Tc with methylenediphosphonate ((99m)Tc-MDP) and hydroxymethylenediphosphonate ((99m)Tc-HMDP), it takes 2-6 h after an injection before imaging can start. This interval could be shortened with a new radiopharmaceutical with higher affinity for bone. Here, based on the concept of bifunctional radiopharmaceuticals, we designed a (99m)Tc-mercaptoacetylglycylglycylglycine (MAG3)-conjugated hydroxy-bisphosphonate (HBP) ((99m)Tc-MAG3-HBP) and a (99m)Tc-6-hydrazinopyridine-3-carboxylic acid (HYNIC)-conjugated hydroxy-bisphosphonate ((99m)Tc-HYNIC-HBP). METHODS: (99m)Tc-MAG3-HBP was prepared by complexation of MAG3-HBP with (99m)Tc using SnCl(2) as a reductant. The precursor of (99m)Tc-HYNIC-HBP, HYNIC-HBP, was obtained by deprotection of the Boc group after the coupling of Boc-HYNIC to a bisphosphonate derivative. (99m)Tc-HYNIC-HBP was prepared by a 1-pot reaction of HYNIC-HBP with (99m)TcO(4)(-), tricine, and 3-acetylpyridine in the presence of SnCl(2). Affinity for bone was evaluated in vitro by hydroxyapatite-binding assays for (99m)Tc-HMDP, (99m)Tc-MAG3-HBP, and (99m)Tc-HYNIC-HBP. Biodistribution experiments for the 3 (99m)Tc-labeled compounds were performed on normal rats. RESULTS: (99m)Tc-MAG3-HBP and (99m)Tc-HYNIC-HBP were each prepared with a radiochemical purity of >95%. In the in vitro binding assay, (99m)Tc-MAG3-HBP and (99m)Tc-HYNIC-HBP had greater affinity for hydroxyapatite than (99m)Tc-HMDP. In the biodistribution experiments, (99m)Tc-MAG3-HBP and (99m)Tc-HYNIC-HBP had higher levels of radioactivity in bone than (99m)Tc-HMDP. (99m)Tc-MAG3-HBP was cleared from the blood slower than (99m)Tc-HMDP, whereas there was no significant difference in clearance between (99m)Tc-HYNIC-HBP and (99m)Tc-HMDP. Consequently, (99m)Tc-HYNIC-HBP showed a higher bone-to-blood ratio than (99m)Tc-HMDP. CONCLUSION: We developed a novel (99m)Tc-chelate-conjugated bisphosphonate with high affinity for bone and rapid clearance from blood, based on the concept of bifunctional radiopharmaceuticals. The present findings indicate that (99m)Tc-HYNIC-HBP holds great potential for bone scintigraphy.
机译:在使用(99m)Tc与亚甲基二膦酸酯((99m)Tc-MDP)和羟基亚甲基二膦酸酯((99m)Tc-HMDP)进行骨闪烁显像时,注射后需要2-6小时才能开始成像。可以使用对骨骼具有更高亲和力的新型放射性药物来缩短该时间间隔。在这里,基于双功能放射性药物的概念,我们设计了一个(99m)Tc-巯基乙酰基甘氨酰甘氨酰甘氨酸(MAG3)共轭的羟基双膦酸酯(HBP)((99m)Tc-MAG3-HBP)和一个(99m)Tc-6-肼基吡啶-3-羧酸(HYNIC)共轭羟基双膦酸酯((99m)Tc-HYNIC-HBP)。方法:使用SnCl(2)作为还原剂,通过将MAG3-HBP与(99m)Tc络合制备(99m)Tc-MAG3-HBP。 (99m)Tc-HYNIC-HBP的前体HYNIC-HBP,是在Boc-HYNIC与双膦酸酯衍生物偶联后,通过Boc基团的脱保护得到的。 (99m)Tc-HYNIC-HBP是通过HYNIC-HBP与(99m)TcO(4)(-),三辛胺和3-乙酰基吡啶在SnCl(2)存在下的1-pot反应制备的。通过(99m)Tc-HMDP,(99m)Tc-MAG3-HBP和(99m)Tc-HYNIC-HBP的羟基磷灰石结合试验评估了骨的亲和力。在正常大鼠上进行了3种(99m)Tc标记化合物的生物分布实验。结果:制备的(99m)Tc-MAG3-HBP和(99m)Tc-HYNIC-HBP的放射化学纯度均> 95%。在体外结合试验中,(99m)Tc-MAG3-HBP和(99m)Tc-HYNIC-HBP对羟基磷灰石的亲和力大于(99m)Tc-HMDP。在生物分布实验中,(99m)Tc-MAG3-HBP和(99m)Tc-HYNIC-HBP在骨中的放射性水平高于(99m)Tc-HMDP。 (99m)Tc-MAG3-HBP从血液中清除的速度比(99m)Tc-HMDP慢,而(99m)Tc-HYNIC-HBP与(99m)Tc-HMDP的清除率无明显差异。因此,(99m)Tc-HYNIC-HBP显示出比(99m)Tc-HMDP高的骨血比。结论:我们基于双功能放射性药物的概念,开发了一种新型(99m)Tc-螯合物-双膦酸酯,对骨骼具有高亲和力并能快速从血液中清除。目前的发现表明(99m)Tc-HYNIC-HBP具有巨大的骨闪烁显像潜能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号